Biotech Patent Dispute Dampens Investor Sentiment... Focus on Scope of Sales Restrictions and Follow-Up Actions

Shares related to a domestic biotech company's formulation-conversion technology weakened after an anticancer drug using the technology was ordered to stop sales in some European countries due to a patent dispute. The technology is used to convert drugs administered by intravenous injection into subcutaneous injections, reducing administration time. Investor sentiment reflected concerns that a prolonged sales restriction could affect sales-linked technology fees and royalty income under technology transfer agreements. However, the order is limited to certain regions, so its impact should be considered separately from the company's global business as a whole.

The drug has received approval in several countries, including the United States, and its overseas developer has challenged the validity of the patent and the finding of infringement, while considering legal action. To assess the impact on the business going forward, it is necessary to consider the duration of the sales restriction, subsequent legal proceedings, and the contractual revenue structure together. Approvals in other regions do not mean the dispute has been resolved, but regional sales conditions are an important factor in assessing the business outlook. Carefully monitoring subsequent actions and actual sales trends can provide a clearer assessment of the business value of the formulation-conversion technology and its potential future applications.

Meanwhile, interest in stock-backed loans has been growing. Investors seeking to avoid missing investment opportunities are turning to stock-backed loans, which allow them to use more funds to purchase shares.

Another advantage of stock-backed loans is that even if a sharp drop in share prices puts investors using margin or credit trading at risk of forced liquidation, they can easily switch to a stock-backed loan without providing additional collateral or selling shares, then wait for a rebound.

All New Stock Loan launches a product with the industry's lowest interest rate, starting in the 5% range per year!

All New Stock Loan has launched a securities-linked credit product available at an industry-low interest rate in the 5% range per year, so investors can try a stock-backed loan without undue burden. The product can be used to purchase shares or refinance margin and credit balances at securities firms. Investors can borrow up to four times their own capital, including that capital, regardless of credit rating. Investors using the alternative trading system (NXT) can also use the service.

Investors who would like to learn more about All New Stock Loan can contact its customer service center at 1599-8666 to speak with a professional counselor at any time, regardless of whether they qualify for a loan.

- Product launched at an industry-low interest rate in the 5% range per year!

- ETF trading available

- Use up to four times your own funds to buy shares! (Including your own capital)

- Same-day refinancing of securities credit or margin balances available!

- Trading through the alternative trading system (NXT) available

- OK to buy stocks that were difficult to purchase using credit from your securities firm or a stock-backed loan!

* All New Stock Loan Customer Service Center: 1599-8666

Visit: https://allnewstockloan.co.kr

Samsung Electro-Mechanics, LG Electronics, Doosan Tesna, Sampyo Cement, SIMMTECH

※ This content does not reflect the editorial direction of The Asia Business Daily. The information provider bears all responsibility.

This content was produced with the assistance of AI translation services.